ImmuneOnco Biopharmaceuticals – HK$319 Million IPO
Hong Kong – September 5, 2023 – Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global initial public offering and listing on the Hong Kong Stock Exchange under stock code 1541. Partners Yiming Liu and Michael Yu led the Cooley team.
Morgan Stanley and China International Capital Corporation served as joint sponsors, overall coordinators, joint global coordinators, joint bookrunners and joint lead managers for the global offering. Fosun International Securities, CMB International, BOCI, ICBC, Soochow Securities and Futu Securities International acted as joint bookrunners and joint lead managers.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.